A spin-off of GammaDelta Therapeutics in London, Adaptate is developing new treatments for cancer, both haematological and solid tumors, using novel antibodies targeting γδ T cells. Unlike GammaDelta Therapeutics whose focus is on the development of cell based therapies, Adaptate Biotherapeutics will carve out a distinct but related area of science by developing non cell based therapies using antibodies.
Total raised: $18M
Investors 1
| Date | Name | Website |
| - | Abingworth... | abingworth... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 19.04.2021 | - | $18M | - | abingworth... |
Mentions in press and media 2
| Date | Title | Description | Category | Author | Source |
| 19.04.2021 | Adaptate B... | - | - | - | abingworth... |
| 19.04.2021 | Adaptate B... | Adaptate Biotherapeutics raise... | - | - | cambridgen... |